Skip to Main Content (Press Enter)

Logo UNISR
  • ×
  • Home
  • People
  • Outputs
  • Organizations
  • Expertise & Skills
  • Equipment

UNIFIND
Logo UNISR

|

UNIFIND

unisr.it
  • ×
  • Home
  • People
  • Outputs
  • Organizations
  • Expertise & Skills
  • Equipment
  1. Outputs

Biomarker analysis of the NeoSphere study: pertuzumab, trastuzumab, and docetaxel versus trastuzumab plus docetaxel, pertuzumab plus trastuzumab, or pertuzumab plus docetaxel for the neoadjuvant treatment of HER2-positive breast cancer

Academic Article
Publication Date:
2017
Short description:
Biomarker analysis of the NeoSphere study: pertuzumab, trastuzumab, and docetaxel versus trastuzumab plus docetaxel, pertuzumab plus trastuzumab, or pertuzumab plus docetaxel for the neoadjuvant treatment of HER2-positive breast cancer / Bianchini, G., Kiermaier, A., Bianchi, G.v., Im, Y.h., Pienkowski, T., Liu, M.c., Tseng, L.m., Dowsett, M., Zabaglo, L., Kirk, S., Szado, T., Eng-Wong, J., Amler, L.c., Valagussa, P., Gianni, L.. - In: BREAST CANCER RESEARCH. - ISSN 1465-5411. - (2017).
Iris type:
1.1 Articolo in rivista
List of contributors:
Bianchini, G; Kiermaier, A; Bianchi, Gv; Im, Yh; Pienkowski, T; Liu, Mc; Tseng, Lm; Dowsett, M; Zabaglo, L; Kirk, S; Szado, T; Eng-Wong, J; Amler, Lc; Valagussa, P; Gianni, L.
Authors of the University:
BIANCHINI GIAMPAOLO
Handle:
https://iris.unisr.it/handle/20.500.11768/153919
Published in:
BREAST CANCER RESEARCH
Journal
  • Use of cookies

Powered by VIVO | Designed by Cineca | 26.11.0.1